Influence of surface and structural properties on the initial release of risperidone from polymeric drug carriers

• Autorzy: Turek A. , Kasperczyk J. , Jelonek K. , Dobrzyński P. , Walichiewicz J. , Krzemińska K. , Smola A. , Musiał-Kulik M. , Marcinkowski A. , Libera M. , Gębarowska K.
• Języki publikacji: EN

Abstrakty

EN

In this work, implantable drug formulation with risperidone on the basis of poly(L-lactide-co-glycolide) (L-PLGA) and poly(D,L-lactide-co-glycolide) (D,L-PLGA) as drug carries was developed. The influence of surface and structural properties on the initial release of risperidone during the first twenty four hours was determined. In this aim, high-performance liquid chromatography, nuclear magnetic resonance spectroscopy, scanning electron microscope and atomic force microscope were used. Significant differences between L-PLGA and D,L-PLGA matrices in all analyzed data were noted. The burst effect was not revealed for any of the studied polymers, however the released drug was almost five times larger for D,L-PLGA matrices. The L-PLGA copolymer revealed a significantly longer average length of the lactidyl and glycolidyl blocks than D,L-PLGA. Moreover, various characters of surface for analyzed matrices were shown, i.e. in case of L-PLGA the surface was porous and in case of D,L-PLGA it was nonporous. Undoubtedly, there were dependences between risperidone's initial release and the topography and the structure of polymeric matrices. We suppose that the larger drug release for L-PLGA was more associated with surface properties and thus structure of matrices. The obtained results showed the great potential of both polymers and possibility to choose the optimal polymer.

Słowa kluczowe

EN

risperidone; implantable drug carriers; poly(L-lactide-co-glycolide); poly(DL-lactide-co-glycolide); initial release

• Wydawca: Polish Society for Biomaterials in Cracow
• Czasopismo: Engineering of Biomaterials
• Rocznik: 2012
• Tom: Vol. 15, no. 116-117 spec. iss.
• Strony: 144--146
• Opis fizyczny: Bibliogr. 19 poz., rys., tab.

Twórcy

autor

Turek A.

• Medical University of Silesia, Department of Biopharmacy, Narcyzów Str., 41-200 Sosnowiec, Poland

autor

Kasperczyk J.

• Medical University of Silesia, Department of Biopharmacy, Narcyzów Str., 41-200 Sosnowiec, Poland
• Polish Academy of Sciences, Centre of Polymer and Carbon Materials, 34 M.Curie-Sklodowskiej Str., 41-819 Zabrze, Poland

autor

Jelonek K.

• Polish Academy of Sciences, Centre of Polymer and Carbon Materials, 34 M.Curie-Sklodowskiej Str., 41-819 Zabrze, Poland

autor

Dobrzyński P.

• Polish Academy of Sciences, Centre of Polymer and Carbon Materials, 34 M.Curie-Sklodowskiej Str., 41-819 Zabrze, Poland

autor

Walichiewicz J.

• Medical University of Silesia, Department of Biopharmacy, Narcyzów Str., 41-200 Sosnowiec, Poland

autor

Krzemińska K.

• Medical University of Silesia, Department of Biopharmacy, Narcyzów Str., 41-200 Sosnowiec, Poland

autor

Smola A.

• Polish Academy of Sciences, Centre of Polymer and Carbon Materials, 34 M.Curie-Sklodowskiej Str., 41-819 Zabrze, Poland

autor

Musiał-Kulik M.

• Polish Academy of Sciences, Centre of Polymer and Carbon Materials, 34 M.Curie-Sklodowskiej Str., 41-819 Zabrze, Poland

autor

Marcinkowski A.

• Polish Academy of Sciences, Centre of Polymer and Carbon Materials, 34 M.Curie-Sklodowskiej Str., 41-819 Zabrze, Poland

autor

Libera M.

• Polish Academy of Sciences, Centre of Polymer and Carbon Materials, 34 M.Curie-Sklodowskiej Str., 41-819 Zabrze, Poland

autor

Gębarowska K.

• Polish Academy of Sciences, Centre of Polymer and Carbon Materials, 34 M.Curie-Sklodowskiej Str., 41-819 Zabrze, Poland

Bibliografia

• [1] http://www.who.int/mental_health/management/schizophrenia/en/.
• [2] McGrath J., Saha S., Chant D., Welham J.: Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 30 (2008) 67-76.
• [3] Asenjo Lobos C., Komossa K., Rummel-Kluge C., Hunger H., Schmid F., Schwarz S., Leucht S.: Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 11 (2010) CD006633.
• [4] Leucht C., Heres S., Kane J.M., Kissling W., Davis J.M., Leucht S.: Oral versus depot antipsychotic drugs for schizophrenia. A critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 127 (2011) 83-92.
• [5] Leucht S., Tardy M., Komossa K., Heres S., Kissling W., Davis J.M.: Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 5 (2012) CD008016.
• [6] Miyamoto S., Miyake N., Jarskog L.F., Fleischhacker W.W., Lieberman J.A.: Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatr 10 (2012) 1038/mp.2012.47.
• [7] Roose K., Gelders Y., Heylen S.: Risperidone (R64 766) in psychotic patients. A first clinical therapeutic exploration. Acta Psychiatr Belg 88 (1988) 233-241.
• [8] Casteläo J.F., Ferreira L., Gelders Y.G., Heylen S.L.: The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64,766) in the treatment of chronic psychosis. An open dose-finding study. Schizophr Res 2 (1989) 411-415.
• [9] Gutierrez R., Lee P.I., Huang M.L., Woestenborghs R.: Risperidone: effects of formulations on oral bioavailability. Pharmacotherapy 17(1997) 599-605.
• [10] Kane J.M., Eerdekens M., Lindenmayer J.P., Keith S.J., Lesem M., Karcher K.: Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiat 160 (2003) 1125-1132.
• [11] Tassaneeyakul W., Kumar S., Gaysonsiri D., Kaewkamson T., Khuroo A., Tangsucharit P., Phunikhom K., Vannaprasaht S., Kanjanawart S., Rao Thudi N., Jain R., Reyar S., Monif T.: Comparative bioavailability of two risperidone orodispersible tablet products after single dose administration. Int J Clin Pharm Th 48 (2010) 614-620.
• [12] Huang M., Shen-Tu J., Hu X., Chen J., Liu J., Wu L.: Comparative fasting bioavailability of dispersible and conventional tablets of risperidone: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy male chinese volunteers. Clin Ther 34 (2012) 1432-1439.
• [13] http://www.ema.europa.eu/docs/pl_PL/document_library/Refer- rals_document/Risperdal_Consta_30/WC5000 08170.pdf.
• [14] Dobrzyński P., Bero M., Kasperczyk J.: Sposób wytwarzania bioresorbowalnych polimerów. Opis patentowy PL 191846 B1 (2000).
• [15] Dobrzyński P., Kasperczyk J., Janeczek H., Bero M.: Synthesis of biodegradable copolymers with the use of low toxic zirconium compounds. 1: Copolymerization of glycolide with L-lactide initiated by Zr(Acac)4. Macromolecules 34 (2001) 5090 -5098.
• [16] Horcas I., Fernandez R., Gómez-Rodriguez J.M., Colchero J., Gómez-Herrero J., Baro A.M. WSXM: a software for scanning probe microscopy and a tool for nanotechnology. Rev Sci Instrum 78 (2007) 013705.
• [17] Trindade R.A., Kiyohara P.K., de Araujo P.S., Bueno da Costa M.H.: PLGA microspheres containing bee venom proteins for preventive immunotherapy. Int J Pharm 423 (2012) 124-133.
• [18] Rafati A., Boussahel A., Shakesheff K.M., Shard A.G., Roberts C.J., Chen X., Scurr D.J., Rigby-Singleton S., Whiteside P., Alexander M.R., Davies M.C.: Chemical and spatial analysis of protein loaded PLGA microspheres for drug delivery applications. J Control Release (2012) [Epub ahead of print].
• [19] Thanki P.N., Dellacherie E., Six J.L.: Surface characteristics of PLA and PLGA films. Appl Surf Sci 253 (2006) 2758-2764.

Uwagi

EN

This work was financially supported by Medical University of Silesia, grant no KNW-1-023/P/2/0.